---
document_datetime: 2025-06-10 11:33:08
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/apexelsin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: apexelsin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.694938
conversion_datetime: 2025-12-24 16:07:33.213714
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Apexelsin

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 10/06/2025                          |                                             | SmPC and PL                      | To update section 4.6 of the SmPC based on the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000272569                        | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.6 of the SmPC based on the Reproductive Toxicity Testing and Labeling recommendations, Food and Drug Administration Guidance (May 2019) and the Non-clinical Working Party/Non- clinical Working Party (S/Nc), European Medicines Agency recommendations (March 2023) on the duration of contraception following the end of treatment with a genotoxic drug. The PL is updated accordingly. The change follows assessment of the same change for the reference product, Abraxane.   |            |     | duration of contraception following the end of treatment with a genotoxic drug. The PL is updated accordingly. The change follows assessment of the same change for the reference product, Abraxane.   |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000268218 | B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 30/04/2025 | N/A |                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000253467   | B.II. FINISHED PRODUCT - B.II.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 17/03/2025   | N/A   |                   |
|-----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------|
| Variation type IA /                     | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted | 15/01/2025   |       | EMA/VR/0000244612 |